title: Generic substitution of antiepileptic drugs: What's a clinician to do?
abstract: Generic substitution of antiepileptic drugs remains a controversial area without a clear consensus to guide clinicians. The US Food and Drug Administration (FDA) requires rigorous testing of generic products and states that all approved products are interchangeable. FDA studies involve single doses in normal subjects so may not represent the performance of generic products in people with epilepsy. Physician surveys, case reports, and retrospective pharmacy database analyses suggest that antiepileptic drug generic substitution is associated with more health problems and high switchback rates, but these studies have insufficient detail on seizure control and blood levels. Several ongoing prospective randomized trials with rigorous pharmacokinetic methods aim to provide more data for decision-making.
authors.affiliation: Department of Neurology, University of Cincinnati, Cincinnati, OH.
authors.forename: Michael
authors.initials: M
authors.lastname: Privitera
references.citation: Epilepsy Curr. 2008 Sep-Oct;8(5):113-7
references.pmid: 18852829
references.citation: Epilepsia. 2007 Mar;48(3):464-9
references.pmid: 17346246
references.citation: JAMA. 1999 Dec 1;282(21):1995
references.pmid: 10591372
references.citation: Epilepsia. 2009 Mar;50(3):493-500
references.pmid: 18616554
references.citation: Ann Pharmacother. 2009 Oct;43(10):1583-97
references.pmid: 19776300
references.citation: Ann Neurol. 2011 Aug;70(2):221-8
references.pmid: 21717495
references.citation: Curr Med Res Opin. 2010 Feb;26(2):455-63
references.pmid: 20014974
references.citation: AAPS J. 2012 Dec;14(4):915-24
references.pmid: 22972221